Name

Alectinib

Alternate Names

Alecensa
ALK inhibitor CH5424802

Abbreviations

None

Category

Chemotherapy

Subcategory

ALK Inhibitor

NSC Number

None

Primary Site

Lung

Histology

Non-small cell lung cancer (NSCLC)

Remarks

UPDATE: December 11, 2015 FDA granted accelerated approval to alectinib for the treatment of anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).

November 6, 2017: FDA granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.

Coding

This drug should be coded
Glossary